Biopharma financing during the second quarter of 2023 totaled $23.8bn from 268 deals. The venture financings category made up the greatest proportion (27%) of the aggregate Q2 financing dollars (see Exhibit 1), with 91 early- and late-stage VC rounds together totaling $6.4bn.
There were 67 biopharmas together raising $3.4bn (14% of the total Q2 dollars) through early-stage rounds and 24 companies bringing...